Description
Product Description
CJC 1295 no DAC – 5 mg
IPAMORELIN – 5 mg
For In Vitro Research Use Only – Not for Human or Veterinary Application
Specifications:
● Quantity: 10 mg
● Form: Lyophilized Powder
Overview
CJC-IPA Blend combines two extensively studied peptides—CJC-1295 no DAC and Ipamorelin—for research into growth factor release, recovery mechanisms, and peptide signaling pathways. This synergistic combination is designed to provide both a stimulatory and sustained peptide effect, offering a versatile tool for laboratory studies.
CJC-1295 no DAC is recognized for its ability to stimulate growth-related pathways over a prolonged period, while Ipamorelin is valued for its selective and targeted activity with minimal off-target interaction. Together, they provide a comprehensive platform for advanced peptide research.
Research Specifics
-
Synergistic Peptide Activity: Studies explore the combined effects of CJC-1295 no DAC and Ipamorelin on growth factor release.
-
Extended Signaling: CJC-1295 no DAC supports prolonged peptide activity in controlled models.
-
Selective Action: Ipamorelin provides targeted stimulation with minimal unwanted pathway activation.
-
Performance & Recovery Models: Blend is used in research examining regeneration and adaptation processes.
Intended Use:
This compound is intended strictly for in vitro laboratory research by qualified professionals. It is not for human or veterinary use and must not be used in food, drugs, diagnostics, or cosmetics.
Disclaimer:
This compound has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. All use must comply with applicable institutional, local, and federal regulations.
Terms of Sale:
By purchasing from VITA LABS, the buyer affirms they are a qualified researcher or institution. All sales are final. The purchaser assumes full responsibility for handling, use, and regulatory compliance. Product Short Description For in vitro laboratory research use only. Not for human or veterinary use
